Sledovať
Jingxin Fu
Jingxin Fu
Research Scientist, Medical Oncology Department, Dana-Farber Cancer Institute
Overená e-mailová adresa na: ds.dfci.harvard.edu - Domovská stránka
Názov
Citované v
Citované v
Rok
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
P Jiang, S Gu, D Pan, J Fu, A Sahu, X Hu, Z Li, N Traugh, X Bu, B Li, J Liu, ...
Nature medicine 24 (10), 1550-1558, 2018
32982018
TIMER2. 0 for analysis of tumor-infiltrating immune cells
T Li, J Fu, Z Zeng, D Cohen, J Li, Q Chen, B Li, XS Liu
Nucleic acids research 48 (W1), W509-W514, 2020
32052020
Large-scale public data reuse to model immunotherapy response and resistance
J Fu, K Li, W Zhang, C Wan, J Zhang, P Jiang, XS Liu
Genome medicine 12 (1), 1-8, 2020
6312020
Landscape of B cell immunity and related immune evasion in human cancers
X Hu, J Zhang, J Wang, J Fu, T Li, X Zheng, B Wang, S Gu, P Jiang, J Fan, ...
Nature genetics 51 (3), 560-567, 2019
1332019
Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade
SS Gu, W Zhang, X Wang, P Jiang, N Traugh, Z Li, C Meyer, B Stewig, ...
Cancer discovery 11 (6), 1524-1541, 2021
1202021
In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target
X Wang, C Tokheim, SS Gu, B Wang, Q Tang, Y Li, N Traugh, Z Zeng, ...
Cell 184 (21), 5357-5374. e22, 2021
1022021
TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response
Z Zeng, CJ Wong, L Yang, N Ouardaoui, D Li, W Zhang, S Gu, Y Zhang, ...
Nucleic acids research 50 (D1), D1391-D1397, 2022
562022
Immune receptor repertoires in pediatric and adult acute myeloid leukemia
J Zhang, X Hu, J Wang, AD Sahu, D Cohen, L Song, Z Ouyang, J Fan, ...
Genome medicine 11, 1-11, 2019
462019
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
L Penter, Y Zhang, A Savell, T Huang, N Cieri, EM Thrash, S Kim-Schulze, ...
Blood, The Journal of the American Society of Hematology 137 (23), 3212-3217, 2021
332021
Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
S Shi, S Gu, T Han, W Zhang, L Huang, Z Li, D Pan, J Fu, J Ge, M Brown, ...
Clinical Cancer Research 26 (22), 5990-6002, 2020
332020
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer
G Oliveira, AM Egloff, AB Afeyan, JO Wolff, Z Zeng, RD Chernock, L Zhou, ...
Science immunology 8 (87), eadf4968, 2023
222023
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
L Zhou, Z Zeng, AM Egloff, F Zhang, F Guo, KM Campbell, P Du, J Fu, ...
Journal for immunotherapy of cancer 10 (1), 2022
222022
Clonal tracing reveals diverse patterns of response to immune checkpoint blockade
SS Gu, X Wang, X Hu, P Jiang, Z Li, N Traugh, X Bu, Q Tang, C Wang, ...
Genome biology 21, 1-28, 2020
172020
Discovery of targets for immune–metabolic antitumor drugs identifies estrogen-related receptor alpha
A Sahu, X Wang, P Munson, JPG Klomp, X Wang, SS Gu, Y Han, G Qian, ...
Cancer discovery 13 (3), 672-701, 2023
132023
Tutorial: integrative computational analysis of bulk RNA-sequencing data to characterize tumor immunity using RIMA
L Yang, J Wang, J Altreuter, A Jhaveri, CJ Wong, L Song, J Fu, L Taing, ...
Nature Protocols 18 (8), 2404-2414, 2023
72023
Cross-site concordance evaluation of tumor DNA and RNA sequencing platforms for the CIMAC-CIDC Network
Z Zeng, J Fu, C Cibulskis, A Jhaveri, C Gumbs, B Das, ...
Clinical Cancer Research 27 (18), 5049-5061, 2021
62021
Cancer Cell Resistance to IFNγ can occur via enhanced double-strand break repair pathway activity
T Han, X Wang, S Shi, W Zhang, J Wang, Q Wu, Z Li, J Fu, R Zheng, ...
Cancer Immunology Research 11 (3), 381-398, 2023
32023
503 Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma
A Afeyan, G Oliveira, AM Egloff, Z Zeng, R Chernock, L Zhou, C Messier, ...
Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022
22022
Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer
AC Garrido-Castro, N Graham, K Bi, J Park, J Fu, T Keenan, ...
Cancer Research 82 (4_Supplement), P2-14-18-P2-14-18, 2022
22022
Data-driven discovery of targets for bipotent anticancer drugs identifies Estrogen Related Receptor Alpha
AD Sahu, X Wang, P Munson, J Klomp, X Wang, S Gu, G Qian, P Nicol, ...
bioRxiv, 2021.10. 25.465724, 2021
2021
Systém momentálne nemôže vykonať operáciu. Skúste to neskôr.
Články 1–20